InMed Pharmaceuticals (MWG) Stock Statistics & Valuation Metrics

InMed Pharmaceuticals has a market cap or net worth of €2.03M. The enterprise value is -€7.37M.

InMed Pharmaceuticals has 2,919,186 shares outstanding. The number of shares has decreased by -2.65% in one year.

InMed Pharmaceuticals’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -41.00%.

The current PE Ratio of InMed Pharmaceuticals is ―. InMed Pharmaceuticals’s PEG ratio is 0.00665.

In the last 12 months, InMed Pharmaceuticals had revenue of 4.94M and earned -8.16M in profits. Earnings per share was -11.44.

In the last 12 months, operating cash flow was -8.91M and capital expenditures 5.00, giving a free cash flow of -8.91M billion.

InMed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

InMed Pharmaceuticals upcoming earnings date is May 18, 2026, Before Open (Confirmed).

InMed Pharmaceuticals as a current ratio of 6.99, with Debt / Equity ratio of 5.55%

In the past 12 months, InMed Pharmaceuticals has paid 0.00 in taxes.

InMed Pharmaceuticals EV to EBITDA ratio is 1.50, with an EV/FCF ratio of 1.40.

InMed Pharmaceuticals has €9.60M in cash and marketable securities with €730.14K in debt, giving a net cash position of €8.87M billion.

Gross margin is 26.50%, with operating margin of -160.20%, and net profit margin of -165.14%.

The average price target for InMed Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―